Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

More than 250 people — a mix of construction crew members, community and business leaders, and Takeda employees — braved ...

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...